Loading...
The immune checkpoint inhibitor pembrolizumab combined with chemotherapy was recently approved by the FDA for first-line treatment of esophageal and gastroesophageal junction squamous cell cancer (SCC) and adenocarcinoma. In China, the anti–programmed death receptor 1 (PD-1) antibody camrelizumab is approved in the second-line treatment of esophageal SCC.
Investigators in China now report results of an industry-sponsored, double-blind, placebo-controlled, randomized, phase 3 trial of camrelizumab (200 mg) combined with first-line chemotherapy (paclitaxel and cisplatin every 3 weeks) in advanced esophageal SCC. Of 596 patients, PD-1 ligand (PDL-1) expression by tumor proportion score (TPS) was positive at ≥1% in 55%, 35% underwent prior esoph…